Lakefront Biotherapeutics | GLPG - Cash And Equivalent


Lakefront Biotherapeutics reported EUR94.66M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
argenx SE USD 2.6B 984M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
Genmab DKK 1.5B 18M Jun/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 486M 27M Sep/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Incyte USD 3.85B 127.8M Sep/2026
Merck EUR 1.96B 788M Jun/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026